11-Dehydro-Thromboxane B2, Urine
Aspirin is an antithrombotic agent which inhibits the platelet function by acetylation of platelet cyclooxygenase, and it can be used in prevention of arterial thromboses due to platelets. Thromboxane (TX) A2 is produced by platelets and has a major role in thrombogenesis at plaque sites. Aspirin is known to reduce the production of TXA2 to inhibit this platelet function. However, 5-60% patients are reported to have ‘aspirin resistance’ where aspirin has little effect on their platelets. Therefore, it was reasoned that monitoring of thromboxane levels might be useful in monitoring the effectiveness of aspirin. However, TXA2 is an unstable molecule with a very short half-life (about 30 seconds) which makes it difficult to measure. TXA2 undergoes inactivation to TXB2 which is further metabolized to a stable product, 11-dehydro thromboxane B2. 11-dehydro thromboxane B2 is excreted through urine and can be measured.
- To assess effectiveness of antiplatelet therapies
- To determine possible benefit of aspirin therapy
- To evaluate coronary heart disease and stroke risk
Increased levels in aspirin users suggest inability of aspirin to inhibit the thrombotic activity of platelet termed as “aspirin resistance”
100-1500 pg/mg creatinine (in patients not taking aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs)
<500 pg/mg creatinine (in healthy individuals taking aspirin)
Random Urine (Sterile Container).
Stability
- Ambient: 7 Days
- Refrigerated: 7 Days
- Frozen: 90 Days
Note: Avoid aspirin 2 weeks before sample collection. Avoid other (NSAIDs) affecting cyclooxygenase pathway 3 days before sample collection.
- Int J Cardiol. 2016; 220: 21-6 [PMID: 27372038]
- Proc Natl Acad Sci U S A. 1986 Aug; 83(16): 5861–5865. [PMID: 3461463]
- World J Diabetes. 2014 Apr 15; 5(2): 115–127. [PMID: 24748925]
- Prostaglandins Other Lipid Mediat. 2018; 134: 24-31 [PMID: 29155368]
- Intern Med. 1992; 31: 735-9 [PMID: 1392173]